Skip to main content

Table 2 Variables associated with Hb reduction > 3 g/dl

From: Erythropoietin rs1617640 G allele associates with an attenuated rise of serum erythropoietin and a marked decline of hemoglobin in hepatitis C patients undergoing antiviral therapy

 

Univariate analysis

Multivariate analysis

Characteristics

Odds ratio [95% CI]

Pvalue

Odds ratio [95% CI]

Pvalue

Week 4

    

  EPO rs1617640 (GG vs. TT/TG)

1.66 [0.92 – 2.94]

0.088

2.17 [1.09 – 4.30]

0.025

  ITPA rs1127354 (additive)

0.35 [0.15 – 0.71]

0.007

0.32 [0.13 – 0.70]

0.007

  Age (years)

0.97 [0.95 – 0.99]

0.0085

0.97 [0.95 – 1.00]

0.02

  Sex (female vs. male)

0.75 [0.44 – 1.26]

0.285

1.64 [0.88 – 3.07]

0.12

  Baseline Hb (g/dl)

2.24 [1.76 – 2.92]

< 0.001

2.50 [1.91 – 3.34]

< 0.001

  RBV starting dose*

2.49 [1.03 – 7.34]

0.011

2.50 [1.03 – 7.34]

0.036

Week 12

  EPO rs1617640 (GG vs. TT/TG)

1.57 [0.92 – 2.70]

0.064

1.97 [1.07 – 3.66]

0.029

  ITPA rs1127354 (additive)

0.60 [0.35 – 1.01]

0.058

0.58 [0.32 – 1.03]

0.067

  Age (years)

0.97 [0.95 – 0.99]

0.002

0.97 [0.95 – 0.99]

0.004

  Sex (female vs. male)

0.86 [0.55 – 1.33]

0.49

1.75 [1.04 – 2.99]

0.084

  Baseline Hb (g/dl)

1.90 [1.55 – 2.35]

< 0.001

2.08 [1.67 – 2.64]

< 0.001

  RBV starting dose*

2.09 [1.20 – 3.79]

0.011

2.18 [1.17 – 4.20]

0.016

  1. Abbreviations: EPO erythropoietin, ITPA inosine triphosphatase, RBV ribavirin, CI confidence interval. *RBV starting dose is coded as an ordered categorical variable with levels of 800, 1000, 1200, and 1400 mg with linear increments.